myelofibrosis

Gilead Fails to Beat Incyte’s Jakafi Drug
Gilead Fails to Beat Incyte’s Jakafi Drug
Investopedia
Gilead Sciences
Jakafi
Incyte
momelotinib
myelofibrosis
Flag link:
Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal
Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal
Endpoints
Shire
myelofibrosis
CTI BioPharma
Baxalta
M&A
pacritinib
Flag link:
Geron shares jump after two positive drug studies
Geron shares jump after two positive drug studies
Marketwatch
Geron
imetelstat
myelofibrosis
essential thrombocythemia
Flag link:
ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival
ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival
TheStreet.com
ASCO
CTI BioPharma
myelofibrosis
pacritinib
Jakafi
Incyte
Flag link:
Baxter and its controversial partner CTI claim a win in PhIII blood cancer study
Baxter and its controversial partner CTI claim a win in PhIII blood cancer study
Fierce Biotech
Baxter
CTI BioPharma
pacritinib
myelofibrosis
Flag link:
Johnson & Johnson (JNJ) Strikes $935 Million Deal With Geron Corporation (GERN) To Co-Develop Imetelstat
Johnson & Johnson (JNJ) Strikes $935 Million Deal With Geron Corporation (GERN) To Co-Develop Imetelstat
Bidness Etc.
JNJ
Geron
imetelstat
myelofibrosis
Flag link:
Incyte Building Blockbuster Drug One Disease At A Time
Incyte Building Blockbuster Drug One Disease At A Time
Investors.com
Incyte
Jakafi
myelofibrosis
Flag link:
Geron Collaborates with J&J for Imetelstat
Geron Collaborates with J&J for Imetelstat
Yahoo/Zacks
Geron
JNJ
imetelstat
myelofibrosis
acute myelogenous leukemia
myelodysplastic syndrome
leukemia
Flag link:
Geron sells last drug in pipeline to J&J unit
Geron sells last drug in pipeline to J&J unit
Yahoo/Reuters
Geron
JNJ
imetelstat
Jakafi
myelofibrosis
Flag link:
After A Long Year, An Update on Geron's Myelofibrosis Drug Is Disclosed
After A Long Year, An Update on Geron's Myelofibrosis Drug Is Disclosed
TheStreet.com
Geron
myelofibrosis
imetelstat
Flag link:
FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
FDA Grants Fast Track Designation to CTI BioPharma's Pacritinib, a Novel JAK2 Inhibitor for the Treatment of Myelofibrosis
Yahoo
pacritinib
FDA
CTI BioPharma
fast track
myelofibrosis
Flag link:
Geron Set To Explode As FDA Releases Partial Clinical Hold On Imetelstat Myelofibrosis Trial
Geron Set To Explode As FDA Releases Partial Clinical Hold On Imetelstat Myelofibrosis Trial
Seeking Alpha
FDA
imetelstat
Geron
myelofibrosis
Flag link:
Geron And The Mayo Clinic Working In Parallel To Release Clinical Hold Of Imetelstat
Geron And The Mayo Clinic Working In Parallel To Release Clinical Hold Of Imetelstat
Seeking Alpha
Geron
imetelstat
myelofibrosis
Flag link:
Geron says FDA halts patient enrollment in another cancer trial
Geron says FDA halts patient enrollment in another cancer trial
Yahoo/Reuters
FDA
Geron
imetelstat
myelofibrosis
Flag link:
Clinical Trial Hold Of Geron's Revolutionary Drug Imetelstat Will Be Temporary
Clinical Trial Hold Of Geron's Revolutionary Drug Imetelstat Will Be Temporary
Seeking Alpha
imetelstat
Geron
clinical trials
myelofibrosis
Flag link:
Geron Plummets as FDA Halts Development of Blood Disorder Drug
Geron Plummets as FDA Halts Development of Blood Disorder Drug
Bloomberg
FDA
Geron
imetelstat
myelofibrosis
Flag link:
Geron Shares React to Imetelstat Mayo Study Update
Geron Shares React to Imetelstat Mayo Study Update
TheStreet.com
Geron
imetelstat
myelofibrosis
Flag link:
Keep an Eye on Geron, Novartis, Cell Therapeutics, and Verastem Today
Keep an Eye on Geron, Novartis, Cell Therapeutics, and Verastem Today
Motley Fool
Verastem
Cell Therapeutics
Novartis
Geron
imetelstat
Jakavi
myelofibrosis
tosedostat
AML
VS-5584
Flag link:
Geron Soars After Study Shows Bone Marrow Drug’s Benefit
Geron Soars After Study Shows Bone Marrow Drug’s Benefit
Bloomberg
Geron
imetelstat
myelofibrosis
Flag link:
Whither Sanofi R&D? Another Setback For An Oncology Drug
Whither Sanofi R&D? Another Setback For An Oncology Drug
Pharmalot
Sanofi
R&D
fedratinib
myelofibrosis
Flag link: